Dichlorphenamide
Keveyis, Ormalvi (dichlorphenamide) is a small molecule pharmaceutical. Dichlorphenamide was first approved as Daranide on 1982-01-01. It is used to treat glaucoma in the USA. It is known to target carbonic anhydrase 1, carbonic anhydrase 12, and carbonic anhydrase 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
Trade Name
FDA
EMA
Keveyis, Ormalvi (discontinued: Keveyis)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dichlorphenamide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KEVEYIS | Xeris Pharmaceuticals | N-011366 RX | 2015-08-07 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dichlorphenamide | ANDA | 2024-11-01 |
| keveyis | New Drug Application | 2024-08-12 |
| ormalvi | ANDA | 2024-02-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| glaucoma | EFO_0000516 | D005901 | H40 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Paralysis | D010243 | HP_0003470 | — | — | — | 2 | — | — | 2 |
| Hyperkalemic periodic paralysis | D020513 | — | G72.3 | — | — | 2 | — | — | 2 |
| Hypokalemic periodic paralysis | D020514 | — | G72.3 | — | — | 2 | — | — | 2 |
| Myotonic disorders | D020967 | Orphanet_606 | G71.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Dichlorphenamide |
| INN | diclofenamide |
| Description | Diclofenamide is a sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma. It has a role as an EC 4.2.1.1 (carbonic anhydrase) inhibitor, an antiglaucoma drug and an ophthalmology drug. It is a sulfonamide and a dichlorobenzene. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 120-97-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL17 |
| ChEBI ID | 101085 |
| PubChem CID | 3038 |
| DrugBank | DB01144 |
| UNII ID | VVJ6673MHY (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CA1
CA1
CA12
CA12
CA4
CA4
Organism
Homo sapiens
Gene name
CA1
Gene synonyms
NCBI Gene ID
Protein name
carbonic anhydrase 1
Protein synonyms
CA-I, CAB, Carbonate dehydratase I, Carbonic anhydrase B, Carbonic anhydrase I, Cyanamide hydratase CA1, epididymis secretory protein Li 11, epididymis secretory sperm binding protein
Uniprot ID
Mouse ortholog
Car1 (12346)
carbonic anhydrase 1 (Q9DC84)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Keveyis – Strongbridge Biopharma
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Keveyis – Xeris Biopharma Holdings
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 274 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,502 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use